ATB Therapeutics SA
17.0 FTEATB Therapeutics reported total assets of €10.6m at the end of the 2025 financial year (annual accounts filed with the NBB on 20 Jul 2026), with 17 full-time equivalents.
By total assets for 2025, ATB Therapeutics ranks among the 50 largest of the 327 companies in its sector (NACE 2110) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of ATB Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +387 % Headcount (avg FTE) +26 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
ATB Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 20 Jul 2026
- Year ended 31 Dec 2024filed on 14 Jul 2025
- Year ended 31 Dec 2023filed on 15 Jul 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
- Year ended 31 Dec 2021filed on 30 Aug 2022
ATB Therapeutics's financial analysis
- Solvency47.8%sector median: 46.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ATB Therapeutics
ATB Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0677.980.015
- VAT number
- BE0677980015
- Peppol
- Registered · 0208:0677980015 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 06 Jul 2017
- Registered office
- 6900 Marche-en-Famenne
- Size
- Small · 17.0 FTE
- Latest accounts
- 2025 · filed on 20 Jul 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
ATB Therapeutics (SA) has been based in Marche-en-Famenne since 2017, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of €8.00m and equity of €5.08m; its revenue is not published. With 17.0 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 47.8%, above the median of its sector (46.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to ATB Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- XpressBioX Manufacture of basic pharmaceutical products Herstal · balance sheet €8.92m
- Etherna Immunotherapies Research and experimental development on natural sciences and engineering Niel · balance sheet €12.8m
- Aquilon Pharmaceuticals Research and experimental development on natural sciences and engineering Seraing · balance sheet €11.1m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- Phoenix Biosciences Manufacture of pharmaceutical preparations Nivelles · balance sheet €8.11m
- Aboleris Holdco Research and experimental development on natural sciences and engineering Charleroi · balance sheet €14.8m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
Frequently asked questions about ATB Therapeutics
What is the revenue of ATB Therapeutics?
ATB Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ATB Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0677980015 for ATB Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0677.980.015.
Where is the registered office of ATB Therapeutics?
According to the CBE register, the registered office of ATB Therapeutics is in 6900 Marche-en-Famenne.
What is the equity of ATB Therapeutics?
At the close of the 2025 financial year, the equity of ATB Therapeutics amounts to 5,081,751 €, a solvency of 47.8% of total assets.
How many people work at ATB Therapeutics?
17.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages ATB Therapeutics?
The register lists 11 active mandates at ATB Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is ATB Therapeutics within its sector?
By total assets for 2025, ATB Therapeutics ranks among the 50 largest of the 327 companies in its sector (NACE 2110) in Belgium that filed accounts for that financial year.
The full file of ATB Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →